The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS

The Influence of Anti-Müllerian Hormone on Ovarian Responsiveness to Ovulation Induction With Gonadotrophins in Women With Polycystic Ovarian Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02673632

Enrollment

Registered

2016-02-04

Start date

2016-02-29

Completion date

2016-08-31

Last updated

2016-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Anti-Müllerian hormone, Ovarian stimulation, Polycystic ovary syndrome, Intracytoplasmic sperm injection

Brief summary

The investigator suggests that PCOS women with high AMH levels are resistant to ovarian stimulation and may need adjustment of the dose of gonadotrophin.

Detailed description

There is a correlation between high levels of AMH and the severity of PCOS. Excessive AMH may have a negative effect on the sensitivity of the resting follicles to gonadotropins. This is an observational prospective study to investigate the impact of circulating AMH on gonadotrophin induction in women with PCOS.

Interventions

DRUGMerional ®

Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Women of age 18 - 35 years * BMI 20 - 30 kg/m2 * Anovulatory infertility * Diagnosis of PCOS based on Rotterdam consensus criteria (two of three criteria: Oligo/anovulation, hyperandrogenaemia and sonographic appearance of polycystic ovaries)

Exclusion criteria

* Women Above 35 years or under 18 years * Women with BMI above 30 kg/m2 or under 20 kg/m2 * Normally ovulating women * Patients with marked hyperandrogenaemia were screened for congenital adrenal hyperplasia (by measuring serum concentration of 17alpha hydroxyl-progesterone) or Patients with Cushing syndrome (by measuring urinary free cortisol)

Design outcomes

Primary

Measure	Time frame	Description
Good response to hMG therapy defined as occurrence of > 3 mature follicles after treatment.	30 days	Good response to hMG therapy defined as occurrence of \> 3 mature follicles after treatment.

Contacts

Primary ContactKarim L Emam, MBBCH

kl_emam@hotmail.com+201001001696

Backup ContactAhmed M Bahaa eldin, A.Professor

abahaa0503@med.asu.edu.eg+20 1111700556

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026